Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxydyan is a nutraceutical supplement developed by the Italian company Ghimas, designed to combat oxidative stress and support cellular energy metabolism. The formulation combines Coenzyme Q10 (ubiquinone) and Vitamin E (alpha-tocopherol), two potent lipid-soluble antioxidants. Coenzyme Q10 acts as an essential electron carrier within the mitochondrial electron transport chain, specifically facilitating electron transfer at Complexes I and II to support the production of adenosine triphosphate (ATP). Simultaneously, both Coenzyme Q10 and Vitamin E function as scavengers of reactive oxygen species (ROS), protecting cellular components and lipid membranes from oxidative damage and lipid peroxidation. Oxydyan is marketed as a food supplement to maintain physiological well-being in conditions characterized by high oxidative demand or mitochondrial insufficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxydyan.